| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
91,060,000 |
| Market
Cap: |
301.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.22 - $5.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aquestive Therapeutics is a pharmaceutical company. Co. is developing orally administered products to deliver various molecules using its proprietary technologies, PharmFilm®. Co.'s products within its central nervous system portfolio, focused on epilepsy, include: Sympazan®, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome; and Libervant™, a buccally, or inside of the cheek, administered soluble film formulation of diazepam, used as an alternative to device-dependent rescue therapies, available to patients with refractory epilepsy, which are a rectal gel and nasal sprays.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
44 |
75,044 |
| Total Sell Value |
$0 |
$0 |
$214 |
$429,899 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Korczynski Sherry |
SVP Sales and Marketing |
• – – |
2025-06-09 |
4 |
D |
$3.54 |
$9,608 |
D/D |
(2,714) |
156,858 |
|
- |
|
| Cioffi Melina |
SVP, Regulatory Affairs |
• – – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
202,261 |
|
- |
|
| Cioffi Melina |
SVP Regulatory Affairs |
• – – |
2025-04-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
182,261 |
|
13% |
|
| Jung Cassie |
Chief Operating Officer |
• – – |
2025-03-10 |
4 |
D |
$2.54 |
$5,542 |
D/D |
(2,182) |
295,526 |
|
- |
|
| Wargacki Stephen |
Chief Science Officer |
• – – |
2025-03-10 |
4 |
D |
$2.54 |
$11,613 |
D/D |
(4,572) |
343,552 |
|
- |
|
| Boyd Peter E. |
See Remark |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$20,355 |
D/D |
(7,681) |
303,323 |
|
- |
|
| Jung Cassie |
Chief Operating Officer |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$21,192 |
D/D |
(7,997) |
297,708 |
|
- |
|
| Toth A Ernest Jr |
Chief Financial Officer |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$23,150 |
D/D |
(8,736) |
339,366 |
|
- |
|
| Wargacki Stephen |
Chief Science Officer |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$40,892 |
D/D |
(15,431) |
348,124 |
|
- |
|
| Braender Lori J |
Chief Legal Officer |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$28,244 |
D/D |
(10,658) |
402,981 |
|
- |
|
| Barber Daniel |
President and CEO |
• – – |
2025-03-09 |
4 |
D |
$2.65 |
$143,095 |
D/D |
(53,998) |
1,015,173 |
|
- |
|
| Boyd Peter E. |
See Remark |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$17,554 |
D/D |
(6,624) |
311,004 |
|
- |
|
| Boyd Peter E. |
See Remark |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
317,628 |
|
- |
|
| Jung Cassie |
Chief Operating Officer |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$19,507 |
D/D |
(7,361) |
305,705 |
|
- |
|
| Jung Cassie |
Chief Operating Officer |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
313,066 |
|
- |
|
| Toth A Ernest Jr |
Chief Financial Officer |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$27,011 |
D/D |
(10,193) |
348,102 |
|
- |
|
| Toth A Ernest Jr |
Chief Financial Officer |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
358,295 |
|
- |
|
| Wargacki Stephen |
Chief Science Officer |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$34,076 |
D/D |
(12,859) |
363,555 |
|
- |
|
| Wargacki Stephen |
Chief Science Officer |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
376,414 |
|
- |
|
| Braender Lori J |
Chief Legal Officer |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$25,419 |
D/D |
(9,592) |
413,639 |
|
- |
|
| Braender Lori J |
Chief Legal Officer |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
423,231 |
|
- |
|
| Korczynski Sherry |
SVP Sales and Marketing |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$14,384 |
D/D |
(5,428) |
159,572 |
|
- |
|
| Korczynski Sherry |
SVP Sales and Marketing |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
165,000 |
|
- |
|
| Barber Daniel |
President and CEO |
• – – |
2025-03-07 |
4 |
D |
$2.65 |
$77,664 |
D/D |
(29,307) |
1,069,171 |
|
- |
|
| Barber Daniel |
President and CEO |
• – – |
2025-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
272,000 |
1,098,478 |
|
- |
|
183 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (1.85%) 
